← The Wire·Breaking·Earnings·

Astra falls 9% after Wainua misses primary endpoint in late-stage trial

AstraZeneca's stock fell ~9% after its Wainua (eplontersen) therapy missed the primary endpoint in a late-stage clinical trial. The trial failure removes a meaningful near-term revenue catalyst and raises questions about the breadth of AstraZeneca's cardiovascular/neurological pipeline.

AstraZeneca’s Discovery Centre, Cambridge — file photoFile photo · AstraZeneca’s Discovery Centre, Cambridge · Nov 2021 · John Sutton · CC BY-SA 2.0 · Source & license

The story

AstraZeneca shares dropped roughly 9% after Wainua (eplontersen), its RNA-targeting therapy developed with Ionis Pharmaceuticals, failed to meet the primary endpoint in a late-stage clinical trial. A Phase 3 miss of this magnitude typically signals that regulatory approval in this indication is off the table without further study design changes or additional trials.

Wainua had represented a meaningful pipeline asset for AstraZeneca, particularly in the cardiometabolic and rare disease space. Ionis Pharmaceuticals, AstraZeneca's partner on eplontersen, is also directly affected, as the collaboration underpins a significant portion of Ionis's commercial-stage revenue outlook. A failed primary endpoint puts milestone payments and royalty streams tied to this program in jeopardy.

The 9% single-day drop in AstraZeneca is notable for a large-cap pharma name, suggesting the market had priced in meaningful probability of success for this indication. The bear case here is straightforward: the trial failure is a binary negative event, and near-term re-rating pressure is likely to persist as analysts revise revenue models to strip out this program.

The bull case rests on AstraZeneca's broad and diversified pipeline — the company has multiple late-stage assets across oncology, respiratory, and rare disease that are unaffected by this result. Whether the selloff represents an overreaction depends on how much of AZN's valuation was attributable to Wainua's upside.

Our read · Thu, Jul 9

AZN and IONS are under pressure after Wainua's Phase 3 miss — the question is whether the selloff is an overreaction given AZN's diversified pipeline or fair repricing of lost milestone and royalty potential.

Why. A primary endpoint miss in a late-stage trial is a binary negative catalyst with no near-term reversal mechanism — analysts must revise models to remove this program, and that process typically extends selling pressure for 1-2 weeks post-announcement. The 9% gap down suggests the market was pricing in meaningful probability of success.

Both cases

The case it holdsAstraZeneca's revenue base is highly diversified across oncology, respiratory, and rare disease, meaning Wainua's failure may represent a modest fraction of total pipeline NPV, potentially making the 9% drop an overreaction relative to fundamentals.
The case it breaksA Phase 3 primary endpoint miss eliminates near-term approval optionality for this indication, forcing sell-side analysts to strip out milestone and royalty projections from models, which typically sustains downward price pressure for weeks following the announcement.

What could change this view: AZN's diversified pipeline and any positive read-across from other ongoing trials could stabilize or reverse the selloff quickly; short covering after the initial gap could squeeze near-term.

AstraZeneca stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

More on AZN

Olema shares slide 15.1% after AstraZeneca SERENA-4 resultsAstraZeneca breast cancer drug fails late-stage trial goalAmgen and AstraZeneca report positive lung cancer trial resultsAstraZeneca discontinues lung cancer trial of volrustomigAstraZeneca's $400bn deal unravels after investor opposition

Latest on the Wire

AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions rise
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Investing.com, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →